Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Last hours
Enjoy this offer
* See conditions under "Our services"

Valuation: Silence Therapeutics plc

Market Cap 236M 317M 273M 252M 443M 29.97B 448M 2.97B 1.16B 14.67B 1.19B 1.16B 50.85B P/E Ratio 2026 *
-10.7x
P/E Ratio 2027 * -10.7x
Enterprise Value 83.46M 112M 96.53M 88.89M 157M 10.59B 158M 1.05B 409M 5.19B 420M 411M 17.97B EV / Sales 2026 *
29.2x
EV / Sales 2027 * -14.1x
Free-Float
69.36%
Yield 2026 *
-
Yield 2027 * -
1 day-4.14%
1 week+11.65%
Current month-2.75%
1 month+10.00%
3 months-8.71%
6 months+7.02%
Current year+10.36%
1 week 6.03
Extreme 6.03
7.18
1 month 5.74
Extreme 5.74
7.29
Current year 4.19
Extreme 4.19
8.4
1 year 4.19
Extreme 4.19
8.4
3 years 1.97
Extreme 1.97
27.72
5 years 1.97
Extreme 1.97
28.35
10 years 1.97
Extreme 1.97
35
Manager TitleAgeSince
Chief Executive Officer 72 2025-12-13
Director of Finance/CFO 54 2022-02-20
Chief Tech/Sci/R&D Officer - 2020-12-31
Director TitleAgeSince
Director/Board Member 63 2018-06-20
Chairman 72 2019-11-30
Director/Board Member 54 2025-12-17
Date Insider Type Main position Quantity % Market Cap.
01-01Free

Director

90,000 0.0635%
01-01Free

Chief Technology Officer

300,000 0.2117%
01-01Free

Chief Financial Officer

375,000 0.2646%
Change 5-day change 1-year change 3-year change Capi.($)
-4.14%+11.65%+32.61%+1.05% 331M
-0.12%+1.04%-13.08%-12.43% 43.58B
-2.17%+4.70%+293.71%+535.99% 34.03B
+0.44%-3.80%+12.51%-17.06% 29.77B
-1.60%-1.58%-0.19%+31.82% 29.82B
-0.29%+9.47%+13.95%+21.93% 25.42B
+3.54%+8.43% - - 13.87B
-1.26%-1.11%+53.37%+108.10% 13.35B
-1.04%-3.48%+2.42%+1.98% 12.85B
-1.18%-2.00%+107.41%+78.18% 12.22B
Average -0.78%+3.06%+55.86%+83.28% 21.52B
Weighted average by Cap. -0.55%+2.03%+60.65%+104.88%

Financials

2026 *2027 *
Net sales 2.86M 3.83M 3.3M 3.04M 5.36M 362M 5.42M 35.95M 14.01M 178M 14.39M 14.08M 615M 4.12M 5.53M 4.77M 4.39M 7.74M 523M 7.82M 51.88M 20.21M 256M 20.76M 20.32M 888M
Net income -49.09M -65.88M -56.78M -52.28M -92.16M -6.23B -93.14M -618M -241M -3.05B -247M -242M -10.57B -80.04M -107M -92.57M -85.24M -150M -10.16B -152M -1.01B -392M -4.97B -403M -395M -17.24B
Net Debt -153M -205M -177M -163M -287M -19.38B -290M -1.92B -749M -9.49B -769M -753M -32.88B -294M -395M -340M -313M -553M -37.35B -558M -3.7B -1.44B -18.29B -1.48B -1.45B -63.38B
Logo Silence Therapeutics plc
Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The Company leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The Company focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.
Employees
88
Date Price Change Volume
26-06-16 6.710 $ -4.14% 216,835
26-06-15 7.000 $ +4.63% 406,276
26-06-12 6.690 $ +0.15% 239,402
26-06-11 6.680 $ +11.33% 700,918
26-06-10 6.000 $ -0.17% 140,944
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
6.710USD
Average target price
31.20USD
Spread / Average Target
+364.98%

Quarterly revenue - Rate of surprise

LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!